Eli Lilly reported second-quarter earnings and revenue that significantly exceeded analyst expectations, driven by strong sales of the diabetes drug Mounjaro and weight loss injection Zepbound. Mounjaro sales were over $3 billion for the quarter, more than triple the prior year and beating estimates. Zepbound sales exceeded $1 billion, above estimates of nearly $900 million. Shares jumped over 9% pre-market on the strong results and outlook increase. Eli Lilly is the largest U.S.-based pharmaceutical company with a market cap of over $730 billion.